What is Valitor?
Valitor is a biotechnology enterprise dedicated to transforming the treatment paradigm for ocular diseases through its innovative multivalent biopolymer technology. The company's primary objective is to enhance patient outcomes by addressing the limitations of current therapeutic delivery methods, specifically targeting conditions such as wet age-related macular degeneration (AMD). Its lead candidate, VLTR-559, represents a significant advancement in the field, engineered to provide extended therapeutic durability. This approach aims to drastically reduce the frequency of intravitreal injections, thereby improving patient compliance and overall quality of life. By bridging the gap between complex biopolymer science and clinical application, Valitor is effectively addressing a critical unmet need in the ophthalmology market.
How much funding has Valitor raised?
Valitor has raised a total of $28M across 1 funding round:
Series B
$28M
Series B (2022): $28M with participation from Berkeley Catalyst Fund, ExSight Ventures, Morningside Group, First Spark Ventures, and Pandect Bioventures
Key Investors in Valitor
Berkeley Catalyst Fund
The Berkeley Catalyst Fund provides essential capital to startups, fostering a robust innovation ecosystem centered around the University of California system and the broader San Francisco Bay Area.
ExSight Ventures
ExSight Ventures is a specialized investment firm focused on ophthalmic diagnostic and treatment solutions, leveraging deep domain expertise from retinal surgeons to support breakthrough life science technologies.
First Spark Ventures
First Spark Ventures is a deep tech fund that invests in transformative technologies across digital biology and biotech, supporting founders from the early stages through to commercialization.
What's next for Valitor?
With this major enterprise-level funding, Valitor is poised to transition from a research-focused entity to a clinical-stage organization. The strategic allocation of capital will likely prioritize the advancement of VLTR-559 through rigorous clinical trials and the expansion of its internal pipeline. Furthermore, the company is expected to leverage its proprietary technology to explore potential collaborations with larger pharmaceutical partners, aiming to validate its platform across a broader spectrum of therapeutic areas. As the firm scales its operations, the focus will remain on achieving key regulatory milestones and demonstrating the long-term efficacy of its biopolymer-based delivery systems in real-world clinical settings.
See full Valitor company page
